home / stock / ivevf / ivevf short
Short Information | Inventiva SA (OTCMKTS:IVEVF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 17,020 |
Total Actual Volume | 20,220 |
Short Trends | |
---|---|
Cover Days | 1 |
Short Days | 10 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 851 |
Average Short Percentage | 47.15% |
Is there a IVEVF Short Squeeze or Breakout about to happen?
See the IVEVF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
11-13-2023 | $3.665 | $3.67 | $3.67 | $3.665 | 3,000 | 3,000 | 100% |
10-07-2022 | $4.95 | $4.95 | $8.4 | $4.95 | 1,500 | 1,100 | 73.33% |
10-06-2022 | $4.1 | $4.1 | $4.19 | $4.1 | 11,500 | 10,000 | 86.96% |
12-03-2021 | $13.64 | $13.64 | $13.64 | $13.64 | 100 | 100 | 100% |
11-22-2021 | $13.08 | $13.08 | $13.08 | $13.08 | 150 | 150 | 100% |
09-30-2021 | $13.18 | $13.18 | $13.18 | $13.18 | 200 | 200 | 100% |
07-16-2020 | $10.84 | $10.84 | $10.84 | $10.84 | 100 | 100 | 100% |
07-13-2020 | $12.5905 | $12.5905 | $12.5905 | $12.5905 | 1,020 | 20 | 1.96% |
07-10-2020 | $15.4 | $14.4 | $15.4 | $14.4 | 1,550 | 1,250 | 80.65% |
07-02-2020 | $13.45 | $13.45 | $13.45 | $13.45 | 100 | 100 | 100% |
05-07-2019 | $2.40 | $2.40 | $2.40 | $2.40 | 1,000 | 1,000 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Daix, 21 June 2024 Pursuant to Article 241-2 of the AMF General Regulations ( Règlement Général de l’Autorité des marchés financiers ), the purpose of this description is to present the objectives and terms of the Company’s share repurchase program a...
Daix (France), Long Island City (New York, United States), on June 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dy...
Daix (France), Long Island City (New York, United States), May 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatit...